
    
      After enrolment upon meeting eligibility criteria (D0), participants baseline data will be
      collected and participants will be randomised to receive either standard of care treatment
      only, or standard of care plus CYP-001. On D1 and D3, each participant randomised to receive
      CYP-001 will receive an IV infusion of 2 million Cymerus mesenchymal stem cells (MSCs)/kg of
      body weight (up to a maximum of 200 million cells). Participants will have further data
      collection throughout their ICU and hospital stay and follow up to 28 days.
    
  